GALAD Score Calculator- Free Hepatocellular Carcinoma HCC Risk Assessment Tool

About This GALAD Score Calculator

This GALAD score calculator is designed for healthcare professionals, researchers, and patients with chronic liver disease who want to understand their hepatocellular carcinoma risk profile. The tool calculates the GALAD Z score and HCC probability from five inputs: patient sex, age, serum alpha-fetoprotein (AFP), AFP-L3 percentage, and des-gamma-carboxy prothrombin (DCP/PIVKA-II), using the validated logistic regression formula published by Johnson et al. in 2014.

The calculator implements the standard GALAD equation (Z = -10.08 + 0.09 x Age + 1.67 x Sex + 2.34 x log10(AFP) + 0.04 x AFP-L3 + 1.33 x log10(DCP)) and converts the resulting Z score to an HCC probability using the logistic function. Results are compared against established clinical cutoff thresholds from phase 2 and phase 3 biomarker validation studies, including the commonly used -0.76 balanced cutoff and the 0.88 high-specificity cutoff.

The visualization combines three complementary display approaches: a horizontal gradient risk bar showing overall HCC probability position, individual reference range bars for each biomarker (AFP, AFP-L3, DCP) against their clinical thresholds, and a live formula breakdown showing how each component contributes to the final Z score. This multi-panel approach helps users understand both the overall risk assessment and the specific biomarker patterns driving their result, supporting informed clinical decision-making alongside professional hepatology consultation.

GALAD Score Calculator: Complete Guide to Hepatocellular Carcinoma Risk Assessment Using Serum Biomarkers

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of cancer-related death worldwide. Early detection of HCC dramatically improves survival outcomes, yet most patients are not diagnosed until they present with symptoms at advanced stages, when treatment options are limited and prognosis is poor. The GALAD score represents a significant advancement in HCC surveillance, combining patient demographics with three serum biomarkers into a single predictive model that outperforms traditional screening methods. This comprehensive guide explains the GALAD score formula, its clinical interpretation, the science behind each component biomarker, and its role in modern hepatocellular carcinoma surveillance programs.

What Is the GALAD Score?

The GALAD score is a statistical model designed to estimate the likelihood of hepatocellular carcinoma in patients with chronic liver disease. The acronym stands for its five components: Gender, Age, AFP-L3 (Lens culinaris agglutinin-reactive alpha-fetoprotein fraction), AFP (alpha-fetoprotein), and DCP (des-gamma-carboxy prothrombin, also known as PIVKA-II or protein induced by vitamin K absence-II). Unlike relying on a single biomarker or imaging alone, the GALAD model integrates these parameters using logistic regression to produce a continuous score that reflects the probability of having HCC.

The model was originally developed by Professor Philip Johnson and colleagues at the University of Birmingham in the United Kingdom, with their foundational study published in Cancer Epidemiology, Biomarkers and Prevention in 2014. The researchers recognized that while individual biomarkers like AFP, AFP-L3, and DCP each had some diagnostic value for HCC, combining them with demographic risk factors could produce a more accurate and reliable prediction. The GALAD model has since been validated in multiple independent cohorts from Germany, Japan, Hong Kong, and the United States, consistently demonstrating superior diagnostic accuracy compared to individual biomarkers or ultrasound alone.

Understanding the GALAD Score Formula

The GALAD score is calculated using a logistic regression equation that produces an intermediate value called the Z score. This Z score is then transformed into a probability value ranging from 0 to 1 (or 0% to 100%) using the logistic function. Each component of the formula contributes differently to the overall score, reflecting its relative importance in predicting HCC presence.

The constant term of -10.08 serves as the baseline intercept, essentially setting the starting point from which the other variables adjust the score. The coefficient for age (0.09) means that for each additional year of age, the Z score increases by 0.09, reflecting the well-established association between advancing age and increased HCC risk. The sex coefficient (1.67) is applied when the patient is male (sex = 1), indicating that male sex substantially increases the predicted risk, consistent with the known male predominance of HCC. The AFP and DCP values are log-transformed (base 10) before multiplication by their respective coefficients (2.34 and 1.33), which accounts for the wide range of values these biomarkers can take across different patients and disease stages. AFP-L3, expressed as a percentage, is multiplied directly by 0.04.

Component Biomarkers Explained

Understanding each component of the GALAD score is essential for interpreting results correctly and recognizing the clinical significance of each biomarker in hepatocellular carcinoma detection.

Alpha-Fetoprotein (AFP)

AFP is the most widely used and longest-established serum tumor marker for HCC. It is a glycoprotein normally produced during fetal development, with levels declining significantly after birth. In adults, AFP levels may become elevated due to hepatocyte regeneration, hepatocarcinogenesis, and certain embryonic cancers. While AFP has been used for HCC surveillance for over 50 years, its diagnostic performance as a standalone marker is limited, with sensitivity around 60% and specificity around 84% at the commonly used threshold of 20 ng/mL. Levels above 200 ng/mL are considered highly suggestive of HCC in patients with liver disease. AFP can also be nonspecifically elevated in chronic hepatitis and cirrhosis without cancer, which reduces its specificity as a standalone diagnostic tool.

AFP-L3 (Lens Culinaris Agglutinin-Reactive AFP)

AFP-L3 is a specific glycoform of AFP that binds to the lectin Lens culinaris agglutinin. Unlike total AFP, which can be elevated in benign liver conditions, AFP-L3 is predominantly produced by malignant hepatocytes. The AFP-L3 percentage (AFP-L3 as a fraction of total AFP) provides greater specificity for HCC compared to total AFP alone. An AFP-L3 percentage of 10% or more is associated with a seven-fold increased risk of developing HCC and warrants intensified surveillance. At the 10% cutoff, AFP-L3 demonstrates approximately 95% specificity but only about 51% sensitivity for HCC detection, making it a highly specific but moderately sensitive marker.

Des-Gamma-Carboxy Prothrombin (DCP/PIVKA-II)

DCP, also known as PIVKA-II (protein induced by vitamin K absence or antagonist-II), is an abnormal form of prothrombin produced by malignant hepatocytes. Under normal conditions, DCP is virtually undetectable in healthy individuals. The abnormal secretion of DCP appears to result from an acquired defect in the posttranslational vitamin K-dependent carboxylation of a prothrombin precursor within HCC cells. DCP has a sensitivity of approximately 60% and specificity of approximately 90% for HCC. Importantly, DCP levels can be affected by medications: vitamin K preparations may cause falsely low values, while vitamin K antagonists (such as warfarin) or certain antibiotics may cause falsely elevated values. Patients on warfarin should be excluded from GALAD score assessment.

Gender and Age

Male sex and advancing age are both well-established independent risk factors for HCC. Men develop HCC at approximately two to three times the rate of women, likely due to a combination of hormonal factors, higher rates of hepatitis B infection, greater alcohol consumption, and other lifestyle-related exposures. The incidence of HCC increases substantially with age, particularly after age 50, reflecting the cumulative effect of chronic liver disease over time. Including these demographic variables in the model significantly improves its discriminative ability compared to biomarker panels alone.

Diagnostic Performance of the GALAD Score

The GALAD score has been extensively evaluated in multiple clinical studies across different populations, consistently demonstrating excellent diagnostic performance for HCC detection. In the original validation studies, the area under the receiver operating characteristic curve (AUC) for the GALAD score was 0.95 for overall HCC detection and 0.92 for early-stage HCC detection. These values significantly exceeded those of individual biomarkers and ultrasound alone.

A landmark phase 2 study conducted at Mayo Clinic and validated through the National Cancer Institute’s Early Detection Research Network (EDRN) demonstrated that at an optimal cutoff of -0.76, the GALAD score achieved 91% sensitivity and 85% specificity for HCC detection. When a more specific cutoff of 0.88 was applied, sensitivity decreased to 80% but specificity increased to 97%. The GALAD score AUC of 0.95 was significantly higher than that of ultrasound alone (AUC 0.82) for HCC detection.

A phase 3 biomarker validation study published in 2024 in Gastroenterology enrolled 1,558 patients with cirrhosis across 7 centers in the United States. In this prospective cohort, 109 patients developed HCC over a median follow-up of 2.2 years. Using the original cutoff of -1.36, the GALAD score demonstrated 82% specificity and 62% sensitivity within 12 months before HCC diagnosis. By comparison, AFP at the same specificity level showed only 41% sensitivity, confirming the significant improvement offered by the GALAD model.

Clinical Interpretation of GALAD Score Results

Interpreting the GALAD score requires understanding both the Z score (raw GALAD output) and the derived probability of HCC. A Z score of 0 corresponds to a 50% probability of HCC, negative scores indicate lower likelihood, and positive scores indicate higher likelihood. For clinical decision-making, the score is typically evaluated against one or more cutoff thresholds, with higher scores warranting more urgent diagnostic workup.

When the GALAD score falls below the lower threshold (such as -1.36), the risk of HCC is considered low, and continued routine surveillance is generally appropriate. Scores in the intermediate range suggest moderate concern and may warrant shortened surveillance intervals or additional imaging studies. Scores exceeding the higher thresholds (such as 0.88) indicate a high probability of HCC and should prompt immediate diagnostic imaging with contrast-enhanced CT or MRI according to established guidelines from organizations such as the American Association for the Study of Liver Diseases (AASLD) or the European Association for the Study of the Liver (EASL).

It is essential to recognize that the GALAD score is not a definitive diagnostic test. Elevated scores reflect increased probability but do not confirm the presence of HCC. Conversely, low scores reduce but do not eliminate the possibility of HCC. The score should always be interpreted in conjunction with clinical context, imaging findings, and the patient’s overall risk profile.

GALAD Score vs. Individual Biomarkers

One of the most compelling aspects of the GALAD model is that it consistently outperforms each of its component biomarkers when used individually. In head-to-head comparisons, the GALAD score AUC exceeds those of AFP, AFP-L3, and DCP across all HCC stages. For instance, in the NASH-specific study from Germany, the GALAD score achieved an AUC of 0.96 for any-stage HCC, compared to 0.88 for AFP, 0.86 for AFP-L3, and 0.87 for DCP individually.

The strength of the combined model lies in its ability to capture complementary information from each biomarker. Some HCC tumors produce high levels of AFP but low DCP, while others show the reverse pattern. Approximately 30-40% of patients with HCC have normal AFP levels, but many of these AFP-negative cases show elevated DCP values. By integrating all three biomarkers with demographic factors, the GALAD model captures a broader range of tumor biology and minimizes the chance of missing any single biomarker pattern.

GALAD Score vs. Ultrasound Surveillance

Current HCC surveillance guidelines generally recommend biannual abdominal ultrasound, with or without AFP testing, for patients at high risk. However, ultrasound has well-documented limitations. Its sensitivity for early-stage HCC detection is only about 47% according to meta-analyses, and performance is further reduced in patients with obesity, metabolic-associated fatty liver disease (MAFLD), and advanced cirrhosis with coarse echotexture. Studies comparing GALAD with ultrasound have demonstrated that the GALAD score AUC of 0.95 significantly exceeds that of ultrasound (0.82) for overall HCC detection.

The GALAD score offers particular advantages in populations where ultrasound is less reliable. In patients with nonalcoholic steatohepatitis (NASH), obesity can significantly impair ultrasound image quality and diagnostic sensitivity. A multicenter study from Germany demonstrated that the GALAD score maintained excellent performance in NASH patients, with an AUC of 0.96 for any-stage HCC and 0.91 for early-stage HCC within Milan Criteria. These findings suggest that the GALAD score could serve as a valuable complement to, or in some settings a substitute for, ultrasound-based surveillance.

A combined model called GALADUS, which incorporates both the GALAD score and ultrasound findings, has been proposed and shows even better performance than either modality alone, suggesting that the optimal surveillance strategy may integrate both serum biomarker testing and imaging.

Validation Across Diverse Populations

The GALAD model has been validated in multiple independent cohorts spanning different geographic regions, ethnicities, and underlying liver disease etiologies. Studies have been conducted in the United Kingdom (where the model was originally developed), Germany, Japan, Hong Kong, Egypt, Thailand, and the United States. Across these diverse populations, the model has demonstrated consistent diagnostic performance, although some variation exists depending on the predominant etiology of liver disease and the prevalence of HCC in the study population.

In viral hepatitis populations (hepatitis B and C), the GALAD score has shown particularly strong performance. In nonviral etiologies such as NASH, alcohol-related liver disease, and autoimmune hepatitis, performance remains high but may show slightly different optimal cutoff values. A systematic review and meta-analysis evaluating the GALAD score across multiple studies confirmed pooled AUC values consistently above 0.90 for overall HCC detection and above 0.85 for early-stage HCC detection.

Some studies suggest that the GALAD score may overestimate risk in certain populations and underestimate it in others, which is why clinicians should consider population-specific data when available. The model was initially developed and validated in cohorts with HCC prevalence ranging from 35% to 49%, and its performance characteristics may differ in populations with substantially different HCC prevalence rates.

Who Should Be Assessed with the GALAD Score?

The GALAD score is intended for risk assessment in patients with established chronic liver disease who are at elevated risk for developing hepatocellular carcinoma. The primary target population includes patients with cirrhosis of any etiology, as cirrhosis is the strongest single risk factor for HCC, present in approximately 80-90% of HCC cases. Beyond cirrhosis, patients with chronic hepatitis B (even without cirrhosis, as HBV can cause HCC in non-cirrhotic livers), advanced fibrosis (F3 or higher), and NASH with advanced fibrosis may also benefit from GALAD-based surveillance.

The test is not appropriate for screening the general population, individuals without known liver disease, or patients who are pregnant (as AFP is physiologically elevated during pregnancy, invalidating the biomarker results). Patients on warfarin or other vitamin K antagonists should not undergo DCP-based testing, as these medications can cause falsely elevated DCP values. Similarly, patients receiving vitamin K supplementation may have falsely low DCP values.

Role of GALAD in HCC Staging and Prognosis

While the GALAD score was primarily developed as a diagnostic tool for detecting HCC, emerging research suggests it may also have prognostic value. A prospective study published in the World Journal of Gastroenterology in 2024 evaluated the GALAD score across Barcelona Clinic Liver Cancer (BCLC) staging categories and found that the model can differentiate between curative-stage (BCLC 0-A) and non-curative-stage (BCLC B-D) HCC. The study identified a GALAD cutoff of 6.83 or higher as predictive of substantial reduction in one-year mortality, with specificity of approximately 73%.

Additionally, serial GALAD measurements after curative treatment such as surgical resection or local ablative therapy have shown promise for monitoring treatment response and detecting recurrence. After successful resection, GALAD scores typically decline below baseline thresholds within three months in patients without recurrence, while those who develop recurrent disease show an initial modest decline followed by a steady increase. This suggests that longitudinal GALAD score monitoring could complement imaging in post-treatment surveillance.

Alternative and Related Scoring Models

Several alternative scoring models have been developed that share components with the GALAD score. The GAAP score (Gender, Age, AFP, PIVKA-II) omits AFP-L3 from the model, making it applicable when AFP-L3 testing is unavailable. The ASAP score (Age, Sex, AFP, PIVKA-II) uses a slightly different formulation of similar variables. A 2025 comparative study found that the optimal cutoff values for detecting HCC were GALAD greater than 0.13, GAAP greater than -0.64, and ASAP greater than -0.71, all achieving sensitivities and specificities above 80%.

The BALAD model (Bilirubin, Albumin, AFP-L3, AFP, DCP) uses the same three biomarkers as GALAD but replaces gender and age with liver function parameters (bilirubin and albumin), making it a prognostic rather than diagnostic model. The BALAD-2 model is a refined version with improved prognostic performance. The GALADUS model combines the GALAD score with liver ultrasound results and has been proposed as an enhanced surveillance strategy that leverages the strengths of both biomarker and imaging-based approaches.

Practical Considerations for GALAD Score Testing

The GALAD score calculation requires specific laboratory measurements of AFP, AFP-L3, and DCP obtained from a serum sample. An important technical requirement is that the AFP and AFP-L3 values used in the GALAD calculation must be obtained using the same analytical platform, specifically the uTASWako i30 system, as values obtained with different assay methods cannot be used interchangeably. This means that a clinician cannot substitute an AFP result from one laboratory system into a GALAD calculation that uses AFP-L3 from a different platform.

The test requires approximately 0.25 mL of serum. Specimens should be centrifuged and aliquoted into a plastic vial, with frozen storage preferred for up to 90 days. The GALAD score is then calculated algorithmically from the measured biomarker values combined with the patient’s age and sex. Results are typically reported as both a raw Z score and a derived probability of HCC.

When one or more biomarker values fall below the lower limit of quantitation (LLOQ), the GALAD score is calculated using the LLOQ values, and the result is reported with a “less than” qualifier to indicate this approximation. Clinicians should be aware that such results may underestimate the true GALAD score.

Limitations and Caveats

Despite its strong diagnostic performance, the GALAD score has several important limitations that clinicians and patients should understand. The model was developed and validated primarily in cohorts with HCC prevalence of 35-49%, which is substantially higher than the HCC incidence in routine surveillance populations (typically 1-5% per year). Performance metrics may differ in lower-prevalence settings, and positive predictive values will be lower in populations with lower disease prevalence.

The clinical performance of the GALAD score varies by the underlying etiology of liver disease and may therefore differ across regions where different etiologies predominate. Medication interference with DCP measurement (warfarin, vitamin K, certain antibiotics) can produce misleading results. The score cannot be used during pregnancy due to physiological AFP elevation. Additionally, non-HCC tumors that produce DCP can cause falsely elevated GALAD scores.

The GALAD score should not be interpreted as absolute evidence for the presence or absence of malignant disease. It provides a probability estimate that must be integrated with clinical judgment, patient history, imaging findings, and other diagnostic information. Rare cases of heterophile antibody interference (such as human anti-mouse antibodies) may also affect immunoassay-based biomarker measurements.

Units and Reference Values for GALAD Components

Each biomarker in the GALAD score has specific units and reference ranges that clinicians should be familiar with. AFP is measured in ng/mL (nanograms per milliliter), with normal values generally below 10 ng/mL in non-pregnant adults. Values above 20 ng/mL are commonly used as a screening threshold, while values above 200 ng/mL in the setting of liver disease are considered highly suggestive of HCC. AFP-L3 is expressed as a percentage of total AFP. An AFP-L3 level of 10% or more is considered elevated and associated with significantly increased HCC risk. DCP is measured in ng/mL, with normal values typically below 7.5 ng/mL. Elevated DCP values suggest HCC or, less commonly, vitamin K deficiency or other DCP-producing tumors.

It is important to note that different laboratories may use slightly different reference ranges and reporting units. Some laboratories report DCP in mAU/mL (milli-arbitrary units per milliliter) rather than ng/mL, with 1 ng/mL approximately equivalent to 1 mAU/mL for the commonly used assay. Clinicians should verify the units used by their reference laboratory when interpreting results and entering values into the GALAD calculator.

Hepatocellular Carcinoma: Global Epidemiology and Risk Factors

Hepatocellular carcinoma is a major global health burden. It is the sixth most common cancer by incidence and the third leading cause of cancer-related mortality worldwide. The geographic distribution of HCC closely follows the prevalence of its major risk factors, with the highest incidence rates observed in East Asia, Southeast Asia, and sub-Saharan Africa, where hepatitis B virus (HBV) infection is endemic. In Western countries, hepatitis C virus (HCV) infection, alcohol-related liver disease, and increasingly NASH/metabolic-associated fatty liver disease are the predominant risk factors.

Other risk factors for HCC include hemochromatosis, alpha-1 antitrypsin deficiency, Wilson disease, autoimmune hepatitis, aflatoxin exposure, diabetes mellitus, obesity, and tobacco use. Cirrhosis of any cause remains the single strongest predisposing factor, present in the vast majority of HCC cases. The rising prevalence of obesity and metabolic syndrome globally is driving an increasing incidence of NASH-related HCC, creating new surveillance challenges as this population may develop HCC even without established cirrhosis.

Current HCC Surveillance Guidelines and the Role of Biomarkers

Major hepatology societies including AASLD, EASL, and the Asian Pacific Association for the Study of the Liver (APASL) recommend biannual HCC surveillance for at-risk populations. The standard approach involves abdominal ultrasound every six months, with or without serum AFP testing. However, there is growing recognition that this strategy has limitations, particularly in obese patients and those with NASH where ultrasound sensitivity is reduced.

Recent guidelines have evolved to acknowledge the potential role of biomarker panels and scoring models as complements to imaging-based surveillance. While the GALAD score has not yet been formally incorporated into all major society guidelines as a primary screening tool, its performance data have been recognized, and it is increasingly used in clinical practice, particularly at major hepatology centers. The FDA-cleared GALAD panel is available through reference laboratories such as Mayo Clinic Laboratories.

The potential for biomarker-based surveillance is particularly relevant in resource-limited settings where access to regular ultrasound may be challenging. The GALAD score requires only a blood draw and can be calculated from laboratory results, making it potentially more accessible and reproducible than operator-dependent imaging techniques.

Future Directions in GALAD Score Research

Ongoing research is exploring several avenues to enhance the utility of the GALAD score and related biomarker models. Combination approaches such as GALADUS, which integrates GALAD with ultrasound findings, show promise for achieving even higher diagnostic accuracy. Novel biomarkers including cell-free DNA, microRNAs, and methylation markers are being investigated as potential additions to the existing model. The GALADM model, which adds a panel of seven plasma cell-free microRNAs to the GALAD components, has shown improved diagnostic performance in hepatitis B-related HCC in early studies.

Large-scale prospective studies continue to refine optimal cutoff values for different clinical scenarios, including screening versus diagnostic workup settings. Studies are also examining the cost-effectiveness of GALAD-based surveillance compared to standard ultrasound-based protocols, which could inform future guideline recommendations. The application of serial GALAD measurements for treatment response monitoring and recurrence detection represents another active area of investigation.

Example GALAD Score Calculations

Frequently Asked Questions

Conclusion

The GALAD score represents a significant advancement in hepatocellular carcinoma surveillance, offering a blood-based diagnostic tool that combines patient demographics with three complementary serum biomarkers into a single, validated risk score. With demonstrated AUC values consistently above 0.90 for overall HCC detection and superior performance compared to individual biomarkers and ultrasound alone, the GALAD model addresses many of the limitations of current surveillance strategies. The score is particularly valuable for patients with NASH, obesity, and other conditions that reduce ultrasound sensitivity, as well as in resource-limited settings where regular imaging may not be available.

While the GALAD score does not replace the need for confirmatory imaging and clinical judgment, it provides an objective, reproducible, and highly informative risk estimate that can guide clinical decision-making. As ongoing research continues to refine optimal cutoff values, validate the score in broader populations, and explore its utility for treatment monitoring and recurrence detection, the GALAD model is likely to play an increasingly central role in HCC surveillance and early detection strategies worldwide. Patients with chronic liver disease should discuss the potential benefits of GALAD score testing with their hepatologist as part of a comprehensive surveillance plan.